Abstract
Angiogenesis is defined as the physiological process by which new blood vessels develop from pre-existing vessels; either by sprouting or intussusception. Inhibition of angiogenesis is one of the most encouraging strategies to manage the growth and metastasis of cancers. The functional and proliferative status of blood vessels is regulated by the balance between various key molecules that either stimulate or inhibit angiogenesis. During quiescence, the “angiogenic switch” is “off”. However, during tumour development pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor, tumour necrosis factor-α and interleukin-1 are pathologically enhanced. Persistent growth of tumour directed capillary networks creates a favourable microenvironment, promoting cancer growth, progression and metastasis. VEGF, particularly VEGF-A, is a key angiogenic factor. Targeting VEGF, its receptors and the downstream signaling cascade, is a viable strategy to prevent tumour growth and metastasis. The present review discusses the role of VEGF in tumour angiogenesis and the current understanding of anti-VEGF therapies as well as refractoriness of anti-angiogenesis cancer therapy.
Keywords: VEGF, tumour angiogenesis, angiogenic balance, anti-VEGF therapy, extracellular matrix, food and drug administration.
Graphical Abstract
Current Vascular Pharmacology
Title:Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Volume: 15 Issue: 4
Author(s): Kodappully Sivaraman Siveen, Kirti Prabhu, Roopesh Krishnankutty, Shilpa Kuttikrishnan, Magdalini Tsakou, Feras Q. Alali, Said Dermime, Ramzi M. Mohammad and Shahab Uddin*
Affiliation:
- Translational Research Institute, Academic Health System, Hamad Medical Corporation, PO Box 3050, Doha,Qatar
Keywords: VEGF, tumour angiogenesis, angiogenic balance, anti-VEGF therapy, extracellular matrix, food and drug administration.
Abstract: Angiogenesis is defined as the physiological process by which new blood vessels develop from pre-existing vessels; either by sprouting or intussusception. Inhibition of angiogenesis is one of the most encouraging strategies to manage the growth and metastasis of cancers. The functional and proliferative status of blood vessels is regulated by the balance between various key molecules that either stimulate or inhibit angiogenesis. During quiescence, the “angiogenic switch” is “off”. However, during tumour development pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor, tumour necrosis factor-α and interleukin-1 are pathologically enhanced. Persistent growth of tumour directed capillary networks creates a favourable microenvironment, promoting cancer growth, progression and metastasis. VEGF, particularly VEGF-A, is a key angiogenic factor. Targeting VEGF, its receptors and the downstream signaling cascade, is a viable strategy to prevent tumour growth and metastasis. The present review discusses the role of VEGF in tumour angiogenesis and the current understanding of anti-VEGF therapies as well as refractoriness of anti-angiogenesis cancer therapy.
Export Options
About this article
Cite this article as:
Siveen Sivaraman Kodappully , Prabhu Kirti , Krishnankutty Roopesh , Kuttikrishnan Shilpa , Tsakou Magdalini , Alali Q. Feras , Dermime Said , Mohammad M. Ramzi and Uddin Shahab *, Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges, Current Vascular Pharmacology 2017; 15 (4) . https://dx.doi.org/10.2174/1570161115666170105124038
DOI https://dx.doi.org/10.2174/1570161115666170105124038 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Review of Pediatric Uveitis
Current Pediatric Reviews Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Current Pharmaceutical Design Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Evidence for Altered LRP/RAGE Expression in Alzheimer Lesion Pathogenesis
Current Alzheimer Research Food-Derived Peptides and Intestinal Functions
Current Pharmaceutical Design Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Anticancer Potential of Doxorubicin in Combination with Green-Synthesized Silver Nanoparticle and its Cytotoxicity Effects on Cardio-Myoblast Normal Cells
Anti-Cancer Agents in Medicinal Chemistry Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Analytical Methods for the Identification of Pigments in Tattoo Inks and Some of Their Physiological Side Effects: A Review
Current Pharmaceutical Analysis Biological Nitration of Arachidonic Acid
Current Vascular Pharmacology Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry